Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Assessing the utility of lymphocyte count to diagnose COVID-19

Michael Fralick, Orly Bogler, Daniel Tamming, Lauren Lapointe-Shaw, Janice Kwan, Terence Tang, Shail Rawal, Jessica Liu, Farad Razak, Amol A Verma
doi: https://doi.org/10.1101/2021.03.17.21252922
Michael Fralick
1Department of Medicine, Sinai Health System, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mike.fralick@mail.utoronto.ca
Orly Bogler
1Department of Medicine, Sinai Health System, University of Toronto
2Department of Medicine, University Health Network, Toronto, Ontario, Canada
3Department of Medicine, University of Toronto, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Tamming
4Li Ka Shing Knowledge Institute, St. Michael’s Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren Lapointe-Shaw
2Department of Medicine, University Health Network, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janice Kwan
1Department of Medicine, Sinai Health System, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Terence Tang
5Institute for Better Health, Trillium Health Partners
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shail Rawal
2Department of Medicine, University Health Network, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Liu
2Department of Medicine, University Health Network, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Farad Razak
4Li Ka Shing Knowledge Institute, St. Michael’s Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amol A Verma
4Li Ka Shing Knowledge Institute, St. Michael’s Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background COronaVirus Disease 2019 (COVID-19) can be challenging to diagnose, because symptoms are non-specific, clinical presentations are heterogeneous, and false negative tests can occur. Our objective was to assess the utility of lymphocyte count to differentiate COVID-19 from influenza or community-acquired pneumonia (CAP).

Methods We conducted a cohort study of adults hospitalized with COVID-19 or another respiratory infection (i.e., influenza, CAP) at seven hospitals in Ontario, Canada.The first available lymphocyte count during the hospitalization was used. Standard test characteristics for lymphocyte count (×109/L) were calculated (i.e., sensitivity, specificity, area under the receiver operating curve [AUC]). All analyses were conducting using R.

Results There were 869 hospitalizations for COVID-19, 669 for influenza, and 3009 for CAP. The mean age across the three groups was 67 and patients with pneumonia were older than those with influenza or COVID19, and approximately 46% were woman. The median lymphocyte count was nearly identical for the three groups of patients: 1.0 ×109/L (interquartile range [IQR]:0.7,2.0) for COVID-19, 0.9 ×109/L (IQR 0.6,1.0) for influenza, and 1.0 ×109/L (IQR 0.6,2.0) for CAP. At a lymphocyte threshold of less than 2.0 ×109/L, the sensitivity was 87% and the specificity was approximately 10%. As the lymphocyte threshold increased, the sensitivity of diagnosing COVID-19 increased while the specificity decreased. The AUC for lymphocyte count was approximately 50%.

Interpretation Lymphocyte count has poor diagnostic discrimination to differentiate between COVID-19 and other respiratory illnesses. The lymphopenia we consistently observed across the three illnesses in our study may reflect a non-specific sign of illness severity. However, lymphocyte count above 2.0 ×109/L may be useful in ruling out COVID-19 (sensitivity = 87%).

Introduction

COronaVirus Disease 2019 (COVID-19) can be challenging to diagnose, because symptoms are non-specific, clinical presentations are heterogeneous, and false negative tests can occur.1 While most patients hospitalized with COVID-19 will have lymphopenia, it is unknown if lymphopenia can differentiate between COVID-19 and other respiratory infections.2 Our objective was to assess the utility of lymphocyte count to differentiate COVID-19 from influenza or community-acquired pneumonia (CAP).

Methods

We conducted cohort study of adults hospitalized with COVID-19 or another respiratory infection (i.e., influenza, CAP) at seven hospitals in Ontario, Canada.3 The influenza cohort and CAP cohort spanned September to April, 2020, and the COVID-19 cohort spanned January to June, 2020 (most recent available data). CAP was identified using a previously developed definition combining a diagnosis of CAP with receipt of antibiotic that is typically used for CAP (in-press). Influenza was defined using ICD10 diagnostic codes (positive-predictive-value > 90%).4 Patients with COVID-19 who also met the criteria for CAP or influenza were assigned to the COVID-19 group. The first available lymphocyte count during the hospitalization was used. Standard test characteristics for lymphocyte count (×109/L) were calculated (i.e., sensitivity, specificity, area under the receiver operating curve [AUC]). All analyses were conducting using R.

Results

There were 869 hospitalizations for COVID-19, 669 for influenza, and 3009 for CAP. The mean age across the three groups was 67 and patients with pneumonia were older than those with influenza or COVID19, and approximately 46% were woman. The median lymphocyte count was nearly identical for the three groups of patients: 1.0 ×109/L (interquartile range [IQR]:0.7,2.0) for COVID-19, 0.9 ×109/L (IQR 0.6,1.0) for influenza, and 1.0 ×109/L (IQR 0.6,2.0) for CAP. At a lymphocyte threshold of 1.0 the sensitivity and specificity for diagnosing COVID was less than 50% (Table 1). At higher lymphocyte thresholds the sensitivity increased and the specificity decreased (Table 1). For example, at a threshold of 2.0 the sensitivity and specificity was 87% and approximately 10%, respectively. The AUC for lymphocyte count was 54% when patients with influenza were the comparator and 51% when patients with CAP were the comparator (Table 1, Figure 1).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1.

Baseline characteristics and test characteristics of lymphocyte count

Figure 1.
  • Download figure
  • Open in new tab
Figure 1.

Receiver operating curve for lymphocyte count and diagnosis of COVID-19

1. Legend: CAP = community acquired pneumonia

Discussion

Among hospitalized adults, the lymphocyte count was similar for patients with COVID-19, influenza, and CAP. The AUC was close to 0.5, indicating that lymphocyte count has similar accuracy to a coin-toss in determining whether the patient has COVID-19 or another respiratory illness. Thus, lymphocyte count alone is unlikely to be useful to differentiate between COVID-19 and other respiratory illnesses. While lymphopenia is non-specific and thus does not help to rule in COVID-19, the absence of a lymphocyte count above 2.0 may help to rule out COVID-19 (sensitivity of 87%). It is unknown if these findings also apply to patients with mild disease who are not hospitalized. Another important limitation of our study is that we lacked data on chronic medical conditions pre-dating the hospitalization known to cause lymphopenia (e.g., hematologic malignancies, autoimmune disorders), however, we expect these conditions to be rare and not differential across the three respiratory illnesses. The lymphopenia we consistently observed across the three illnesses in our study may reflect a non-specific sign of illness severity, with limited diagnostic utility in identifying underlying etiologies.5

Data Availability

Not available.

Footnotes

  • Study concept and design: Fralick M, Bogler O, Razak F, Verma A, Tamming D

  • Acquisition of data: All authors

  • Analysis/interpretation of data: All authors

  • Drafting of the manuscript: Fralick M

  • Critical revision of the manuscript: All authors

  • Statistical analysis: Tamming D, Fralick M

  • Obtained funding: This study was funded by Sinai Health and the Canadian Institutes of Health Research (Grant Number VR4 - 172743). The development of the GEMINI data platform has been supported with funding from the Canadian Cancer Society, the Canadian Frailty Network, the Canadian Institutes of Health Research, the Canadian Medical Protective Agency, Green Shield Canada Foundation, the Natural Sciences and Engineering Research Council of Canada, Ontario Health, the St. Michael’s Hospital Association Innovation Fund, the University of Toronto Department of Medicine, and in-kind support from partner hospitals and Vector Institute. F.R. is supported by an award from the Mak Pak Chiu and Mak-Soo Lai Hing Chair in General Internal Medicine, University of Toronto.

  • Conflicts of interest: Amol Verma and Fahad Razak are employees of Ontario Health, outside of this project. Mike Fralick is a consultant for a start-up company based at the Massachusetts Institute of Technology (MIT) developing a CRISPR based diagnostic test for COVID19.

References

  1. 1.↵
    Murk W, Gierada M, Fralick M, Weckstein A, Klesh R, Rassen JA. Diagnosis-wide analysis of COVID-19 complications: an exposure-crossover study. CMAJ. 2021;193(1):E10–E18.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Guan W-J, Ni Z-Y, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020:1–13.
  3. 3.↵
    Verma AA, Guo Y, Kwan JL, et al. Patient characteristics, resource use and outcomes associated with general internal medicine hospital care: the General Medicine Inpatient Initiative (GEMINI) retrospective cohort study. CMAJ Open. 2017;5(4):E842–E849.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    Hamilton MA, Calzavara A, Emerson D, et al. Validating International Classification of Disease 10th Revision algorithms for identifying influenza and respiratory syncytial virus hospitalizations. PLoS One. 2021; 16(1): e0244746.
    OpenUrl
  5. 5.↵
    Hohlstein P, Gussen H, Bartneck M, et al. Prognostic Relevance of Altered Lymphocyte Subpopulations in Critical Illness and Sepsis. J Clin Med. 2019;8(3):353.
    OpenUrl
Back to top
PreviousNext
Posted March 20, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Assessing the utility of lymphocyte count to diagnose COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Assessing the utility of lymphocyte count to diagnose COVID-19
Michael Fralick, Orly Bogler, Daniel Tamming, Lauren Lapointe-Shaw, Janice Kwan, Terence Tang, Shail Rawal, Jessica Liu, Farad Razak, Amol A Verma
medRxiv 2021.03.17.21252922; doi: https://doi.org/10.1101/2021.03.17.21252922
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Assessing the utility of lymphocyte count to diagnose COVID-19
Michael Fralick, Orly Bogler, Daniel Tamming, Lauren Lapointe-Shaw, Janice Kwan, Terence Tang, Shail Rawal, Jessica Liu, Farad Razak, Amol A Verma
medRxiv 2021.03.17.21252922; doi: https://doi.org/10.1101/2021.03.17.21252922

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (215)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1093)
  • Dentistry and Oral Medicine (195)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (499)
  • Epidemiology (9757)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2303)
  • Geriatric Medicine (221)
  • Health Economics (462)
  • Health Informatics (1553)
  • Health Policy (732)
  • Health Systems and Quality Improvement (602)
  • Hematology (236)
  • HIV/AIDS (501)
  • Infectious Diseases (except HIV/AIDS) (11631)
  • Intensive Care and Critical Care Medicine (616)
  • Medical Education (236)
  • Medical Ethics (67)
  • Nephrology (256)
  • Neurology (2139)
  • Nursing (134)
  • Nutrition (335)
  • Obstetrics and Gynecology (426)
  • Occupational and Environmental Health (517)
  • Oncology (1172)
  • Ophthalmology (363)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (145)
  • Palliative Medicine (50)
  • Pathology (309)
  • Pediatrics (694)
  • Pharmacology and Therapeutics (298)
  • Primary Care Research (265)
  • Psychiatry and Clinical Psychology (2172)
  • Public and Global Health (4645)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (455)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (208)
  • Surgery (250)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)